Cutaneous toxicity with subepidermal blisters and dyskeratosis following administration of pemetrexed in a patient with nivolumab-induced psoriasis and linear IgA bullous dermatosis
Sayuri Yokomizo
Department of Dermatology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan
Search for more papers by this authorCorresponding Author
Tomoko Miyake
Department of Dermatology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan
Correspondence
Tomoko Miyake, Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan.
Email: [email protected]
Search for more papers by this authorYoshio Kawakami
Department of Dermatology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan
Search for more papers by this authorKadoaki Ohashi
Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan
Search for more papers by this authorHiroshi Koga
Department of Dermatology, Kurume University School of Medicine, Fukuoka, Japan
Search for more papers by this authorNorito Ishii
Department of Dermatology, Kurume University School of Medicine, Fukuoka, Japan
Search for more papers by this authorShin Morizane
Department of Dermatology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan
Search for more papers by this authorSayuri Yokomizo
Department of Dermatology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan
Search for more papers by this authorCorresponding Author
Tomoko Miyake
Department of Dermatology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan
Correspondence
Tomoko Miyake, Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan.
Email: [email protected]
Search for more papers by this authorYoshio Kawakami
Department of Dermatology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan
Search for more papers by this authorKadoaki Ohashi
Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan
Search for more papers by this authorHiroshi Koga
Department of Dermatology, Kurume University School of Medicine, Fukuoka, Japan
Search for more papers by this authorNorito Ishii
Department of Dermatology, Kurume University School of Medicine, Fukuoka, Japan
Search for more papers by this authorShin Morizane
Department of Dermatology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan
Search for more papers by this author
REFERENCES
- 1Hanna N, Shepherd FA, Fossella FA, Pereira JR, Marinis FD, Pawel JV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004; 22: 1589–1597.
- 2Tummino C, Barlesi F, Tchouhadjian C, Tasei AM, Gaudy-Marqueste C, Richard MA, et al. Severe cutaneous toxicity after pemetrexed as second line treatment for a refractory non small cell lung cancer. Rev mal Respir. 2007; 24: 635–638.
- 3Bosch-Barrera J, Gaztañaga M, Ceballos J, Pérez-Gracia JL, López-Picazo JM, García-Foncillas J, et al. Toxic epidermal necrolysis related to pemetrexed and carboplatin with vitamin B12 and folic acid supplementation for advanced non-small cell lung cancer. Onkologie. 2009; 32: 580–584.
- 4Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Jr FC, Sznol M, et al. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol. 2018; 79: 1081–1088.
- 5Jonna S, Neiders M, Lakshmanan S, Khan A, DeKlotz T, Lanasa D, et al. Linear IgA disease of the gingiva following nivolumab therapy. J Immunother. 2019; 42: 345–347.
